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The chorionic villi of human term placentae are a rich source of mesenchymal stem cells (PMSCs). The
stem cell ‘‘niche’’ within the chorionic villi regulates how PMSCs participate in placental tissue gener-
ation, maintenance and repair, but the anatomic location of the niche has not been deﬁned. A number of
cell surface markers for phenotypic characterisation of mesenchymal stem cells (MSCs) were employed
to identify the stem cell niche within the chorionic villi of ﬁrst trimester and term human placenta. This
included antibodies to pericyte cell surface markers STRO-1 and 3G5, which have been used to identify
mesenchymal stem cells in other tissues, but have not been studied in placental tissues. PMSCs were
isolated from term human placentae and shown to have stem cell properties by their ability to grow on
untreated plastic culture ware, capacity for forming clones (i.e. clonogenicity) and their capability to
differentiate into adipocytes, chondrocytes and osteocytes. Western analysis conﬁrmed that STRO-1 and
3G5 are present in placental protein extracts and in PMSCs. Immunocytochemistry revealed PMSCs were
positive for MSC cell surface markers (STRO-1, 3G5, CD105, CD106, CD146, CD49a, a-SMA) and negative
for haematopoietic stem cell markers (CD117, CD34) and endothelial markers (CD34, vWF). Immuno-
histochemistry with antibodies to MSC cell surface markers on ﬁrst trimester and term tissues revealed
a vascular niche for PMSCs. Dual-label immunoﬂuorescence analysis was used to compare STRO-1
antibody staining with that of endothelial cell marker vWF and found no signiﬁcant overlap in staining.
This indicated that some PMSCs have a pericyte-like phenotype. We propose that the vascular niche
harbours a pool of PMSCs that can give rise to committed progenitors for tissue maintenance and repair,
and that PMSCs contribute to vessel maturation and stabilization.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
The chorionic villi from human term placentae are a rich source
of MSCs. The potential utility of PMSCs in therapeutic and regen-
erative medicine drives current research into their in vitro proper-
ties. The (trans)differentiation potential of PMSCs in vitro is now
well known but there is scant knowledge of the natural distribution
and biology of PMSCs in the chorionic villi of the placenta.
PMSCs are readily isolated from term placentae using a variety
of methods. The most popular, routinely used method involvesedicine, The Royal Women’s
ngton Rd., Parkville, Victoria
53746.
. Kalionis).
All rights reserved.mechanical mincing of the chorionic placental tissue, followed by
enzymatic digestion and seeding in stem cell-speciﬁc medium [1].
PMSCs selectively attach to the plastic cultureware, proliferate
rapidly and are usually prepared without additional enrichment
strategies [2]. PMSCs can be differentiated in vitro under speciﬁc
stimulatory environments into derivatives of the mesenchymal cell
lineage such as osteocytes, adipocytes, myocytes and chondrocytes
[1,3–7]. In addition, there is evidence of differentiation in vitro into
cell types characteristic of other lineages such as hepatocyte-like
cells and neural-like cells [3,4,7–11], but in vivo evidence for such
differentiation is very limited.
Various combinations of cell surface markers are used for the
phenotypic characterisation of PMSC in vitro. Common positive
markers for PMSCs are also used to identifyMSCs fromother sources
and include CD90 (Thy-1), CD105 (endoglin), CD29 (beta 1 integrin),
CD44 (hyaluronic acid), and CD73 (lymphocyte-vascular adhesion
N.M. Castrechini et al. / Placenta 31 (2010) 203–212204protein 2). PMSCs are consistently negative for speciﬁc endothelial
cell surface markers [e.g. von Willebrand Factor (vWF), CD34 and
CD45] and haematopoietic stem cell markers (CD34, CD117).
Despite the extensive phenotypic characterisation of PMSCs in
vitro with cell surface markers, there have been no studies to
exploit multiple cell surface markers to identify the microenvi-
ronment, or niche, of PMSCs in the chorionic villi of placental
tissues.
The stem cell niche is a highly balanced microenvironment that
allows stem cells to survive and remain quiescent and then respond
by replicating, migrating and differentiating to replace or repair
tissue when needed [12–14]. This balance between stem cell
proliferation and differentiation is regulated through intracellular
integration of a multitude of signals initiated by internal and
external stimuli. The identiﬁcation of the anatomic location of the
stem cell niche within the placental chorionic villi not only
provides clues as to the nature of these stimuli but can also reveal
additional roles for stem cells in placental development and
function.
Recent studies have employed a panel of cell surface markers
associated with endothelial cells (vWF, CD34), pericytes and endo-
thelial cells (CD146), smooth muscle cells (a-smooth muscle actin),
and pericyte-speciﬁc antigens (STRO-1 and 3G5) to detect cells with
MSC properties in bone marrow, periodontal ligament, dental pulp
and human adipose tissue [15–18]. Importantly, these antibody
markers were used to deﬁne the MSC niche in these tissues.
Furthermore, in these studies the STRO-1, 3G5 and CD146 anti-
bodies were able to enrich for subpopulations of progenitor MSCs
[15,18–22] that have a high capacity to formﬁbroblastoid colonies in
vitro (called the CFU-F population) [22], which is an important
property of stem cells. CFU-F colonies derive from a single stem cell
and have the ability to differentiate intomany of the cells types that
are characteristically derived from the niche [23].
Although STRO-1 and 3G5 antibodies have been used to identify
in vitro cultured MSCs derived from the various sources described
above, they have not been used for the characterisation of the PMSC
niche in the chorionic villi. FACS analysis showed that freshly iso-
lated cells from the placental chorionic villi express STRO-1 and
that expression fell to undetectable levels after passage 3 of in vitro
culture [3]. Another study however, could not detect STRO-1
expression in PMSCs [2]. 3G5 has not been tested as a cell surface
marker for PMSCs and the expression patterns of STRO-1 and 3G5
in the placenta are not known.
Another marker which has been used to enrich the CFU-F
population is CD49a [24]. Integrin alpha 1 (CD49a/VLA-1), which is
the receptor for laminin and collagen, was also investigated. The
CD49a cell surface marker has also been used to identify both
human bone marrow mesenchymal stem cells [25] and PMSCs [1].
FACS analysis has been used routinely for the analysis of PMSC
populations [1,3–7]. In this study, we used cell surface markers,
including STRO-1, 3G5, CD146 and CD49a that enrich CFU-F pop-
ulations, to characterise PMSC preparations by immunohisto-
chemistry. PMSC properties were further demonstrated by CFU-F
and differentiation assays. Finally, we used immunohistochemical
and immunoﬂuorescence studies to identify the anatomic location
of the stem cell niche and to determine differences in the stem cell
niche between early and late pregnancy.
2. Materials and methods
2.1. Patient details
There were 20 term human placentae collected for this study,
with an average patient gestation of 38.51.6 weeks (mean SD),
maternal age of 32.9 6.9 years, baby weight of 3419.0 438.9 gand placental weight of 641.6 90.4 g. Delivery mode was either
elective Caesarean section (15/20) or vaginal delivery (5/20) and
there were 12/20 males and 8/20 females. All samples were
obtained from uncomplicated pregnancies and were therefore
considered normal.
First trimester placental tissues were collected with the consent
and the approval of the Federation of Medical Scientiﬁc Associa-
tions of the Netherlands. The Research and Ethics Committee of the
Royal Women’s Hospital (Victoria, Australia) approved the use of
term placenta tissue for this work. The study was performed in
accordance with the National Health and Medical Research Council
of Australia guidelines. All placental tissues were collected from
healthy women who had medically uncomplicated pregnancies.
Five ﬁrst trimester samples were used in this study.
2.2. Antibodies
Monoclonal antibodies STRO-1 (mouse IgM anti-human stromal
stem cells) [22] and 3G5 (IgM anti-human islet cells; ATCC) were
used as undiluted tissue culture supernatants with total protein
concentration of 4.7 mg/ml and 3.5 mg/ml, respectively. CD146
(used at 4 mg/ml), was a gift of S. Gronthos and A. Zannettino,
Institute of Medical and Veterinary Science, Adelaide, Australia].
Other antibodies included rabbit anti-integrin CD49a/VLA-1 (used
at 8 mg/ml), mouse anti-human CD105 and CD106 (used at 1 mg/ml
and 5 mg/ml respectively) (all from Millipore/Chemicon, Massa-
chusetts, USA) and mouse anti-human a-smooth muscle actin (a-
SMA, used at 4 mg/ml) (Sigma–Aldrich, St. Louis, USA). Endothelial
cell surface markers were rabbit polyclonal anti-human vWF and
mouse anti-human CD34 (QBEnd/10) (Labvision/Neomarkers, Cal-
ifornia, USA) (both used at 1 mg/ml), which have been previously
used for immunohistochemical studies of the placenta [26]. The
haematopoietic stem/progenitor cell surface marker used was
mouse anti-human CD117 (used at 5 mg/ml) (Millipore/Chemicon,
Massachusetts, USA). Control monoclonal antibody FDO66Q (Q66)
(mouse IgG1 anti-human trophoblast cells) [27] was used at 1 mg/
ml and obtained from Flinders Technologies, Pty. Ltd. Adelaide,
Australia. Non-immune rabbit serum (NIRS, used at 5 mg/ml),
control mouse monoclonal antibody1A6.12 (IgM), which was used
as an undiluted tissue culture supernatant with a total protein
concentration of 10 mg/ml (gift of S. Gronthos and A. Zannettino,
Institute of Medical and Veterinary Science, Adelaide, Australia)
was used as a negative control. The other negative control was X63
(mouse IgG1 anti-human), from the cell line P3X63.Ag8, which has
no known cross-reactivity with human tissue, was used at 5 mg/ml
[28] and was obtained from the Department of Immunology
(Flinders Medical Centre, Adelaide, Australia).
2.3. First trimester placental sample collection
First trimester samples (10–12 weeks gestation) were collected
by chorionic villus sampling by a transcervical approach, using
a biopsy catheter (Cook, K-CMA-5000), at the University Hospital
Groningen, The Netherlands. The samples collected were required
for cytogenetic diagnosis and the surplus tissue was parafﬁn
embedded and donated to this study.
2.4. Term placental sample collection
Term placentae were from either from normal vaginal deliveries
or elective Caesarean sections and samples were processed within
20 min of delivery.
Following collection, the decidual surface of the placenta was
removed and 2.5 cm cubes of placental tissue were taken from
a central cotyledon of the villous vascular bed. The samples were
Fig. 1. Western analysis was used to show that CD49a, 3G5 and STRO-1 were expressed in both PMSC protein extracts (PMSC) and in term placental tissue homogenates (tissue). (A)
The CD49a antibody detected bands at 210 kDa, 80 kDa and 70 kDa band in tissue and PMSC protein extracts. (B) The 3G5 antibody, detected a predominant immunoreactive band
at 15 kDa, with minor bands at 10 kDa and 30 kDa for both term placental tissue homogenate and PMSC protein extracts. (C) The STRO-1 antibody detected a prominent 27 kDa
band for both term placental tissue homogenate and PMSC protein extracts. Minor bands at 18 kDa and 50 kDa were also observed. The control blots with NIRS (A) for CD49a/VLA-1
(A) and IA6.12 (B, C) for STRO-1 and 3G5 showed no bands.
Table 1















a þþ, strong staining; þ, moderate staining; þ/, weak staining; , no staining.
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protein extraction, formalin ﬁxed for parafﬁn embedding, encased
in Cryomatrix (Zeiss, Australia) and snap frozen for immunohisto-
chemistry, or placed in warmed Hanks Balanced Salt Solution
(Invitrogen/Gibco, California, USA) for stem cell isolation.
2.5. Isolation of stem cells from term placental tissue
Placental mesenchymal stem cells isolated from term placenta
were prepared as previously described by [1] with the modiﬁca-
tions described below. Placental sections of about 10 g (2.5 cm
cubes) were extensively minced and then centrifuged at 550 g for
5 min. The pellet was then haemolysed in red blood cell lysis buffer
(155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 8.0), centrifuged
at 550 g for 5 min at room temperature. The pellet was incubated at
37 C in 0.05% Trypsin-EDTA solution (Invitrogen/Gibco, California,
USA) for 10 minutes, resuspended twice in 50% a-MEM medium/
50% FBS, subjected to centrifugation at 550 g for 10 min at room
temperature and then plated in a-MEM medium supplemented
with 20% FCS, 0.02% L-ascorbate-2-phosphate, 1% L-Glutamine, 0.5%
penicillin/streptomycin, 0.5% Fungizone and 1% Tylosin. Cells were
maintained in culture at 37 C and 5%CO2. Cell viability and number
was determined by Trypan Blue exclusion assay (Invitrogen, Cal-
ifornia, USA).
2.6. Western immunoblotting
Total protein from cultured stem cells was prepared using
extraction buffer containing 50 mM glycine, 1 mM AEBSF and 0.5%
Triton X-100. Cells were lysed by three freeze–thaw cycles and then
gently homogenised using a 19-gauge needle before centrifugation
at 3000 g for 5 min. Total protein was extracted from whole
placental tissues as described previously [26]. Brieﬂy, 500 mg of
snap-frozen placental tissue was added to 4 ml of extraction buffer
[50 mM glycine, 1 mM AEBSF, 5 mM EDTA (pH 8) and 0.5% Triton
X-100]. Samples were then homogenised on ice, using an Ultra
Turrax T25 mechanical homogeniser for 1 min, followed by
centrifugation at 2500 g for 10 min. Total protein concentration in
the supernatants was determined by Pierce (Thermo Fisher/Pierce,
MA, USA) protein assay reagent using bovine serum albumin
(Sigma, Australia) as the standard.
Immunoblotting was performed according to methods
described previously under reducing conditions [26]. Brieﬂy, 25 mg
of protein per lane was diluted in SDS-PAGE loading buffer
(100 mM Tris–HCl, pH 6.8, 200 mM b-mercaptoethanol, 4% SDS,
0.2% bromophenol blue, 20%glycerol) and boiled for 5 min per lanewas fractionated using 10%Tris–HCl polyacrylamide (BioRad,
California, USA) gel electrophoresis and then transferred to nitro-
cellulose membranes. Membranes were incubated in blocking
agent consisting of 5% skim milk powder in Tris-buffered saline
(pH 7.4) for 1 h at room temperature, followed by incubation with
primary antibodies to either STRO-1, 3G5 or CD49a overnight at
4 C. Membranes were then incubated with goat anti-mouse or
donkey anti-rabbit biotinylated secondary antibody (Dako,
Glostrup, Denmark), followed by streptavidin-HRP (Dako, Glostrup,
Denmark). Tyramide Signal Ampliﬁcation (Perkin–Elmer, MA, USA)
was used, following the manufacturer’s instructions, to amplify the
immunoreactivity. Immunoreactivity was visualised by chem-
iluminescence using the ECL-Plus kit (G.E. Healthcare, Buck-
inghamshire, England) and autoradiography.
2.7. Immunocytochemistry
Cells for immunocytochemical analysis were seeded into an 8-
well chamber slides (BD, Australia) at a density of 50–100 cells/
well, were maintained at 37 C in 5%CO2 for at least 48 h and then
ﬁxed in 10% formalin for 20 min. Antibody staining and detection
was as described below.
2.8. Immunohistochemistry
Immunohistochemical analysis was carried out as described
previously [26]. Brieﬂy, ﬁve micron thick sections of parafﬁn, or
Cryomatrix-embedded whole placental tissue samples, were cut
for immunohistochemistry and placed onto coated slides
Fig. 2. Immunocytochemical staining of isolated PMSCs. Cells were negative for X63 (a), vWF (b) and NIRS, FDO66Q, CD34, and CD117 (data not shown). Cells were positive for 3G5
(c), CD146 (d), CD49a/VLA-1 (e), a-smooth muscle actin (a-SMA) (f), STRO-1 (g) and CD106 (h) (magniﬁcation 200). Cultured cells were clonogenic as shown by colony forming
unit assay (Fig. 1i) (magniﬁcation 100).
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Parafﬁn embedded samples were de-waxed in Xylene and rehy-
drated in graded ethanol before use.
Immunostaining was performed using primary antibodies and
a Histostain-Plus Broad Spectrum Kit (Invitrogen/Zymed,
California, USA). A Tyramide Signal Ampliﬁcation (TSA) kit (Perkin–
Elmer, MA, USA) was used to amplify immunoreactivity from
antibodies to 3G5 and STRO-1 according to the manufacturer’s
instructions. Detection was either by 3-amino-9-ethyl-carazole
(AEC) (Zymed, California, USA) staining with 0.05% methyl green
counterstain or by 3,3-diaminobenzidine (DAB) staining with
haematoxylin counterstain, depending on antibody compatibility.
All slides were mounted in 80% glycerol, visualised using a Zeiss
Axioscop microscope, and analysed with Axiovision software (Carl
Zeiss Inc. New York, USA).
2.9. Dual-labelling immunoﬂuorescence
Frozen placental sections were used for staining and were
treated in the same manner as for immunohistochemistry
described above with the followingmodiﬁcations. Polyclonal rabbit
anti-human vWF antibody was incubated with mouse anti-human
STRO-1. Donkey anti-rabbit Cy-3 conjugated secondary antibody
and goat anti-mouse FITC-conjugated secondary antibody (Milli-
pore/Chemicon, Massachusetts, USA) followed. A mountant con-
taining DAPI nuclear counterstain (CAMBIO, Cambridge, UK) wasFig. 3. Differentiation assays for cells in the mesenchymal lineage. Control undifferentiated P
for the same time as the controls but in a-MEM medium containing differentiation factors. S
Alizarin Red for osteocytes. Magniﬁcation for panels (a) and (b) was 100 and for panels (c)used. Sections were visualised using a ﬂuorescence microscope
(Carl Zeiss, Inc., New York, USA). The staining for vWF (Cy3), STRO-1
(FITC), as well as DAPI nuclear staining, was detected with indi-
vidual ﬁlters and was subsequently composited using the Adobe
Photoshop Elements version 4.
2.10. Colony Forming Unit (CFU) assay
Colony forming efﬁciency was assessed using methods
described previously [29]. Isolated PMSCs at passage two were
seeded into six well plates at a density of 100 cells/well in alpha-
MEM medium supplemented with 20% FCS, 0.02% L-ascorbate-2-
phosphate, 1% L-Glutamine, 0.5% penicillin/streptomycin, 0.5%
Fungizone and 1% Tylosin. Unreplenished day 14 cultures were
ﬁxed with 10% formalin and then stained with haematoxylin.
Aggregates of 50 cells were scored as colonies.
2.11. Differentiation of PMSCs
PMSCs were seeded into 8-well chamber slides at a density of
100 cells per well. Cells incubated with a-MEM medium (supple-
mented with 10% FCS, 0.02% L-ascorbate-2-phosphate, 1% L-Gluta-
mine, 0.5% penicillin/streptomycin, 0.5% Fungizone and 1% Tylosin)
were used as the control. PMSCs were incubatedwith adipogenic or
chondrogenic or osteogenic differentiationmedium. Themedium in
each well was replenished every 48 h. Differentiation media wereMSCs (a, c, e) were grown in a-MEMmedium alone. Panels (b), (d), (f) show cells grown
taining was with Alcian Blue for chondrocytes (a, b), Oil red O for adipocytes (c, d) and
–(f) was 200. The arrows in panel (d) show lipid droplets. Scale bars represent 50 mm.
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tiationwas induced as permanufacturer’s instructions. At the end of
experimental procedures, the cells were ﬁxed in 10% formalin and
stained. Cell stains for mesenchymal stem cells were carried out as
described previously [10,30,31]. Cells were stained with Oil Red-O
and haematoxylin counterstain to detect adipocytes and Alizarin
red solution to detect osteocytes as recommended by the manu-
facturer. Alcian blue counterstainwere used to detect chondrocytes
using the monolayer staining method as described previously [44].
Each stain was performed in duplicate for each sample. Results
were then visualised using a Zeiss Axioscop microscope and ana-
lysed with Axiovision software (Carl Zeiss Inc., New York, USA).Fig. 4. Immunohistochemical localization on parafﬁn sections of cell surface markers in ﬁrs
antibody staining the syncytiotrophoblast layer (b). STRO-1 (c), CD146 (d), CD49a/VLA-1 (
scattered cells around the vessels (arrows). CD34 (g) and vWF (h) show antibody staining o
a haematoxylin counterstain. Panels (g) and (h) show AEC staining and a methyl green coun
vessels; and tr, syncytiotrophoblast cells. Staining of cells is shown by an arrow.3. Results
3.1. Isolation of stem cells from term placental tissue
Placental stem cells were isolated from term human placentae
and grown on untreated plastic cultureware. The mean cell
number within a 25 cm2 ﬂask was 9105. These cells were
conﬂuent for passaging about every 2 weeks. Stem cell cultures
could be passaged up to ﬁve times (about 30 population
doublings). All experiments in these studies were performed with
cells at passage two and each experiment was repeated three or
more times.t trimester (12 week) human placenta. X63 negative control (a) and FDO66Q, a control
e) and 3G5 antibody staining of cells around the vessels (f). 3G5 antibody staining in
f endothelial cells lining the villous vessels. Panels (a)–(f) show staining with DAB and
terstain. Images are 400 magniﬁcation and the scale bar represents 50 mm. v, Villous
N.M. Castrechini et al. / Placenta 31 (2010) 203–212 2093.2. Western immunoblotting
Western analysis was used to show that STRO-1 and 3G5 were
expressed in both PMSC protein extracts and in term placental
tissue homogenates (n¼ 5). CD49a/VLA-1 was used as a control as
it is expressed in placental tissue and FACS analysis shows PMSCs
are positive for this cell surface marker [1]. In placental tissue and
PMSC extracts, the CD49a antibody revealed the expected 210 kDa
and 80 kDa bands [32] and a minor 70 kDa band (Fig. 1A). The 3G5
antibody (Fig. 1B) detected a predominant, immunoreactive but
diffuse band at 15 kDa, and minor bands at 10 kDa and 30 kDa, for
both term placental tissue homogenate and PMSC protein extracts.
The STRO-1 antibody detected a prominent 27 kDa band for both
term placental tissue homogenate and PMSC protein extracts
(Fig. 1C). Minor bands at 18 kDa and 50 kDa were also observed.
Control blots with NIRS and the IA6.12 antibody showed no bands
(Fig. 1A and B respectively).Fig. 5. Immunohistochemical localization of cell surface markers in term human placenta. X6
layer (b). STRO-1(c), CD146 (d), CD49a/VLA-1 (e) and 3G5 (f) antibody staining in the vascu
endothelial cells of the villous vasculature. Antibodies were used on either frozen (a, b, c, d &
staining with AEC and a methyl green counterstain. Panels (b)–(e) show staining with DA
represents 50 mm. v, Villous vessels; and tr, syncytiotrophoblast cells. Staining of cells is sh3.3. Immunocytochemistry on cultured PMSC
Ten independent preparations of PMSCs were analysed quali-
tatively by immunocytochemistry. The panel of cell surfacemarkers
and the signal staining intensities are shown in Table 1. Represen-
tative staining on cultured cells is shown in Fig. 2. Cultured cells
were negative for X63 (Fig. 2a), vWF (Fig. 2b), NIRS, trophoblast cell
surface markers FDO66Q, CD34 and CD117 (data not shown). Most
of the cells (>90%) were positive for 3G5 (Fig. 2c), CD146 (Fig. 2d),
CD49a/VLA-1 (Fig. 2e), a-SMA (Fig. 2f), CD105 (data not shown),
STRO-1 (Fig. 3g) and CD106 (Fig. 3h).
3.4. Colony forming unit assay
Cultured cells were clonogenic as shown by colony forming unit
assay (Fig. 2i). Circular clusters of ﬁve or more cells were counted as
colonies. Seeding at 100 cells per well resulted in 14.3 3.6%3 negative control (a) and FDO66Q, a control antibody staining the syncytiotrophoblast
lar region of the villous vessels. CD34 (g) and vWF (h) control antibodies staining the
f) or parafﬁn (e, g & h) sections depending on antibody speciﬁcity. Panel a and f-h show
B and a haematoxylin counterstain. Images are 400 magniﬁcation and the scale bar
own by an arrow.
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average of 49.8 8.2 cells/colony (n¼ 6, 24 colonies counted for
each sample).
3.5. Differentiation of PMSCs into adipocytes, osteocytes and
chondrocytes
Cells were also incubated with a-MEM medium supplemented
with 10% FCS in each plate as a control (Fig. 3a). PMSCs were tested
for their ability to differentiate into osteocytes (Fig. 3b), adipocytes
(Fig. 3c) and chondrocytes (Fig. 3d) with incubation in either
osteogenic, adipogenic or chondrogenic differentiation media, as
shown by positive Alizarin Red, Oil red O and Alcian Blue staining
respectively (n¼ 6). Control cells showed no morphological
changes during culturing and did not stainwith any of the cell-type
speciﬁc stains described above (data not shown).
3.6. Immunohistochemical localisation of PMSCs in the ﬁrst
trimester and term placenta
Mesenchymal stem cell surface markers STRO-1, 3G5, CD146
and CD49a were chosen for further analysis by immunohisto-
chemistry (n¼ 10). All antibodies, except STRO-1 and 3G5, gave
strong signals on cultured PMSCs. STRO-1 and 3G5 antibodies
required TSA ampliﬁcation to visualise the signal. All tissues incu-
bated with control NIRS and X63 showed no immunoreactivity in
either ﬁrst trimester or term placental sections (X63 in Figs. 4a and
5a, NIRS data not shown). Control antibody FDO66Q showed
speciﬁc immunoreactivity only in syncytiotrophoblast cells, in both
ﬁrst trimester (Fig. 4b) and term placentae (Fig. 5b). CD34 and vWF
showed positive staining of endothelial cells in ﬁrst trimester
(Fig. 4g and h, respectively) and term placental villous vasculature
(Fig. 5g and h, respectively). In ﬁrst trimester placental tissue,
STRO-1 (Fig. 4c), CD146 (Fig. 4d), CD49a (Fig. 4e) all showed
immunoreactivity around the vessels. 3G5 (Fig. 4f) staining was
speciﬁc to scattered cells around the vessels. In term placental
tissue, the spatial distribution of antibody staining was not
substantially different to ﬁrst trimester with STRO-1 (Fig. 5c),
CD146 (Fig. 5d), CD49a (Fig. 5e) and 3G5 (Fig. 5f) showingFig. 6. Dual-label immunoﬂuorescence staining with STRO-1/vWF (a–f) on term frozen pla
rescein detection (green) (b), combined images of (a), (b) are shown in (c) with a DAPI nuc
shown in panels (d)–(f). vWF antibody staining with Cy3 (d), STRO-1 staining with ﬂuorescein
vWF antibody staining with Cy3 detection (f). NIRS and X63 controls showed low or no back
50 mm. Arrowheads in (c) and (f) show representative staining of STRO-1 in cells within thimmunoreactivity around the vessels, and again 3G5 staining was
speciﬁc to individual scattered cells around the vessels. In term
placental sections, larger vessels also showed the same staining
pattern with the cell surface markers (data not shown). No
immunoreactivity was detected in the cytotrophoblast or syncy-
tiotrophoblast cell types, which were revealed by the Q66 antibody
(Figs. 4b, 5b and data not shown).
3.7. Dual-labelling immunoﬂuorescence
Immunoﬂuorescence staining was carried out with the endo-
thelial cell surface marker vWF, and STRO-1 (n¼ 5). The endothelial
cell surface marker, rabbit anti-human vWF antibody, was used
with a donkey anti-rabbit Cy3 conjugated secondary antibody
(Fig. 6a, d) combined with mouse STRO-1 anti-human antibody and
a goat anti-mouse FITC-conjugated secondary antibody (Fig. 6b, e)
and a blue DAPI counterstain to show cell nuclei (Fig. 6c, f). Fluo-
rescence detection revealed discrete cells staining for the STRO-1
antibody around the vessels of various sizes (Fig. 6b and e).
Composite images (Fig. 6c, f) showed immunoreactivity with STRO-
1 was localised to the vascular regions of the term placental villi
and did not overlap signiﬁcantly with expression of vWF in endo-
thelial cells that comprised the vessel walls (indicated by arrows in
Fig. 6c, f). NIRS and X63 showed no speciﬁc staining (data not
shown).
4. Discussion
The method of Fukuchi et al. [1], which is used routinely to
prepare PMSCs, was employed to prepare cultured cells. Exposing
cultured cells to speciﬁc media formulations that promote differ-
entiation for 2–3 weeks produced cells that were positive for cell-
type speciﬁc stains. Differentiation into cells with characteristics of
adipocytes, osteocytes and chondrocytes was observed. These
PMSCs preparations contained clonogenic cells as revealed by
colony forming assays, with a variable frequency of colony forming
units that was consistent with other studies [33].
Western analysis revealed that CD49a immunoreactive protein
was detected in PMSC, as expected since this cell surface marker iscental sections; vWF antibody staining with Cy3 (red) (a), STRO-1 staining with ﬂuo-
lear counterstain stain. Staining from another placenta with vessels of various sizes is
(e), combined images of (d), (e) are shown in (f) with a DAPI nuclear counterstain stain
ground staining (data not shown). Images are 400 magniﬁcation and the scale bar is
e vascular region.
N.M. Castrechini et al. / Placenta 31 (2010) 203–212 211used for phenotypic analysis of PMSC [1]. Western analyses
revealed STRO-1 and 3G5 immunoreactive proteins were detected
in PMSC and term placental extracts, but at low levels since it was
necessary to amplify the signals.
Immunocytochemistry revealed the ﬁbroblast-like cells
produced by this method stained positively with antibodies to the
cell surface markers (CD146, CD49a, CD105, CD106 and a-SMA
STRO-1, 3G5, and CD49a), which have been used to identify MSCs
and PMSCs using FACS analysis. This included antibodies to proteins
that have been used to enrich CFU-F populations (CD146, STRO-1,
3G5, and CD49a). As expected, PMSCs were negative for the
endothelial cell surface marker vWF and the haematopoietic cell
surface marker CD34. Unlike FACS analysis, TSA ampliﬁcation was
necessary to detect 3G5 and STRO-1 staining by immunocyto-
chemistry, and the staining intensity was not uniform in the pop-
ulation. These data are consistent with the notion that PMSCs
prepared in this manner are heterogeneous populations. Since
cultured cells stain positively for STRO-1 and 3G5 antibodies, and
can differentiate along the mesenchymal stem cell lineage, we
propose that STRO-1 and 3G5 are cell surface markers for cultured
PMSCs. We successfully prepared PMSCs as revealed by the ability
of the cells to differentiate into multiple cell types, CFU assays and
the immunocytochemical detection of cell staining with a panel of
MSC cell surface markers.
Immunohistochemical analysis on ﬁrst trimester and term
placental sections was used to identify the stem cell niche.
Immunohistochemical staining with antibodies that have been
used to enrich CFU-F populations inMSCs preparations and that are
associated with mesenchymal and perivascular cells (STRO-1, 3G5,
CD146 and CD49a), produced consistent staining patterns around
the blood vessels. The staining distribution between ﬁrst trimester
and term placentae was similar, suggesting that the spatial location
of the niche does not change substantially after the ﬁrst trimester.
The vascular staining pattern of STRO-1, 3G5, CD146 is consistent
with that seen for these antibodies in human adipose tissues [18]
and in the human endometrium for CD146 [45] and these datawere
used to identify a vascular niche in these tissues. Recently, the
frizzled-9 antibody (FZD-9) was shown to be a cell surface marker
for PMSCs and can also be used to enrich the CFU-F population
[10,34]. The FZD-9 antibody also detects cells in a vascular niche in
the term placenta [10]. These data further support a vascular niche
within the chorionic villi.
Dual-label ﬂuorescence immunohistochemistry with STRO-1
and vWF further reﬁned the niche to scattered cells around the
vessels. There was no signiﬁcant overlap in STRO-1 staining with
vWF staining of the endothelial cells that line the vessels and this is
consistent with previous ﬁndings by others [15]. These data are
consistent with the proposed model of MSCs lying in, or attached
to, the basement membrane opposed to endothelial cells [35].
Mesenchymal stem cells have been shown to exhibit a perivascular
cell phenotype both in vitro and in vivo [18,35]. In response to
intrinsic and extrinsic factors, the PMSCs would give rise to
committed progenitors that incorporate into the surrounding
stroma to effect maintenance and repair.
There may be multiple subpopulations of PMSCs in the vascular
niche. STRO-1 and 3G5 are cell surface markers for pericytes
[15,36–38] and therefore it is likely that one subpopulation of
PMSCs detected by these antibodies in the chorionic villi are peri-
cyte-like cells, or they are indeed pericytes. In vivo studies have
provided evidence that pericytes might act as a source of undif-
ferentiated cells during adipose and osseous tissue repair [39,40].
The possibility that MSCs are derived from pericyte cells has been
raised in several studies [15,18,38,41,42]. Mouse gene knockout
studies highlight the critical importance of pericytes in the matu-
ration and stability of the placental vasculature [43]. We proposethat the pericyte-like PMSCs contribute to the pool of recruited
cells, which respond to growth factors and cytokines derived from
the local villous microenvironment, and which subsequently
regulate vessel maturation and stabilization within the chorionic
villi of the human placenta.
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